Related Experiment Video
Updated: Mar 11, 2026
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
An impressive response to pazopanib in a patient with metastatic endometrial carcinoma
M J van der Steen1, Y R P de Waal, A Westermann
1First auteur: Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands Second auteur: Gynaecological Oncology, Amsterdam Medical Centre, Amsterdam, the Netherlands.
Abstract:
The incidence of endometrial carcinoma is rising and the patients with distant metastases have a poor prognosis, especially when progression of disease occurs after systemic treatment with hormonal therapy or chemotherapy. Pazopanib, a multi-targeted inhibitor of several oncogenic receptor tyrosine kinases, has been investigated in patients with chemotherapy-resistant endometrial carcinoma or patients for whom chemotherapy is contraindicated. In this report we will describe a spectacular response to pazopanib in a patient with recurrent metastatic endometrial carcinoma.
Insights
Endometrial carcinoma is increasing, with poor outcomes for metastatic patients. Pazopanib showed a remarkable response in a patient with recurrent metastatic endometrial carcinoma resistant to standard treatments.
Area of Science:
- Oncology
- Medical Research
Background:
- Endometrial carcinoma incidence is rising globally.
- Patients with distant metastases face poor prognoses, particularly after treatment failure.
Observation:
- Pazopanib, a tyrosine kinase inhibitor, targets multiple oncogenic pathways.
- Its efficacy is being explored in chemotherapy-resistant or contraindicated endometrial carcinoma cases.
Findings:
- This report details a significant positive response to pazopanib in a patient with recurrent, metastatic endometrial carcinoma.
- The patient experienced a "spectacular response" to the treatment.
Implications:
- Pazopanib may represent a promising therapeutic option for advanced endometrial carcinoma.
- Further investigation is warranted to confirm its role in managing treatment-resistant disease.
More Related Videos
08:12Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
